

Q&A of Financial Results for the 1st Quarter of the Year Ending March 31, 2026

Disclaimer

This document (Q&A of financial results) is not a verbatim transcript of the questions and answers that took place at the presentation as of August 7, 2025.

Rather, the Company has exercised its discretion in providing a summary for those who did not participate.

Also, forward-looking statements, such as performance forecasts and the like, provided in these materials are based on certain assumptions and may differ significantly from actual business results as a result of a variety of factors.

The company-wide

Q: Please share the assumptions used to calculate the US tariff impacts announced today.

A: We expect the full-year impact on operating profit to be ¥7.5B. Tariff rates used in the assumptions were 15% for Japan and the EU, 19% for Thailand, 55% for China, and 10% for the UK. The estimated impacts consider inventories held at US subsidiaries as well as price adjustments and resulting demand contractions, among other factors, but do not consider secondary impacts from tariffs such as economic stagnation. By segment, more than 60% of the tariff impacts are to be felt in the Imaging Products Business, just under 30% in the Healthcare Business, and the remaining 10%+ across the other business segments.

Q: Please describe the difference between the ¥7.5B in US tariff impacts on operating profit announced today versus the ¥10.0B announced previously.

A: The May estimates used rough tariff rate approximations. This time, we used the latest rates and considered factors such as the recent demand trends to estimate the impact of price adjustments.

Q: Please explain the progress of Q1 results versus the company's plan.

A: Company total revenue lagged by about ¥5.0B and operating profit by about ¥3.0B versus internal plans. Tariff impacts on Q1 operating profit was about ¥1.3B, but these tariff impacts were not factored into internal plans. By segment, Imaging Products felt the tariff impacts, but unused expenses helped the business finish roughly in line with plan. The Components Business saw sales pulled forward and therefore beat plan in revenue and operating profit. Meanwhile, the postponement

of some sales caused the Precision Equipment Business, Healthcare Business, and Digital Manufacturing Business to lag plan. Company-total operating profit missed plan mainly due to the Healthcare Business and Digital Manufacturing Business.

Imaging Products Business

Q: Aside from tariff impacts, why have you left unchanged your other assumptions in 2H guidance? Please share your outlook.

A: Global market conditions are unclear. The situation needs to be closely examined and carefully assessed. Therefore, we have reflected only tariff impacts in our 2H business performance projections. There may be downside risk if product mixes shift downward going forward.

Precision Equipment Business

Q: As a result of harsh market conditions for some US cutting-edge logic chips, semiconductor production and inspection equipment makers have faced order cancellations and requests for returns. Has your Semiconductor Lithography Business been impacted?

A: There has been no impact because, since the beginning of the fiscal year, we have assumed limited sales of semiconductor lithography systems to the US given the business environment.

Q: What is the Precision Equipment service business situation this fiscal year?

A: We expect a year-on-year decline in Semiconductor Lithography Business revenue for maintenance and service, with a modest recovery starting in 2H.

Q: Please explain the competitive differentiation points and feedback on the digital lithography system DSP-100 that you began taking orders for in July.

A: Our digital lithography system DSP-100 has strengths in a wide-angle lithography field and high productivity and enjoys a competitive edge in applications for data centers such as AI servers that incorporate large-format chips. Currently, multiple customers have inquired or evaluated our system, and we are making solid progress toward launch next fiscal year.

Q: Please describe demand for G10 FPD lithography systems.

A: There is active demand for large 65" and 75" panels, which are well-suited for G10 FPD lithography systems, and production capacity expansion is anticipated. However, this has not yet translated into demand for new systems at this time. Nikon

endeavors to provide service-related items to help customers raise productivity.

Healthcare Business

Q: Aside from tariff impacts, why have you left unchanged your other assumptions in 2H guidance?

A: In Life Science Solutions, we were impacted by the cutoff or suspension of grants to academia in the US, but more recently the resumption of some grants has led to signs of a recovery in orders. So, there may be a recovery in 2H. In Eye Care Solutions, although there was a bit of a reversion downward in 1H after sales were pulled forward into Q4 of the previous fiscal year, we expect a recovery in 2H. We are also making progress opening underdeveloped channels in Europe and Asia and expect full-year revenue to be flat year-on-year.

Components Business

Q: **Please describe sales for EUV related components. Are there any changes to demand in Q2 and beyond?**

A: We expect Nikon's sales of EUV related components to trend in line with last year. The semiconductor market recovery in cutting-edge fields that use EUV lithography is delayed, and end customers may postpone the timing of their investments.